Media release
|
Thursday 14th July 2005 |
Text too small? |
The agreement with medical products company Brightwake will allow Comvita to extend their medical product range, building on the early success of Comvita's ApiNate wound dressing.
Comvita launched ApiNate Dressings in New Zealand and overseas markets earlier this year. The novel wound dressings combine absorbent alginate (seaweed) fibres with medical grade active manuka honey. More and more hospitals, rest homes and general practitioner surgeries around the world are taking it up, according to Comvita chief executive, Graeme Boyd.
He says the deal with Brightwake ensures that we have the necessary manufacturing capability to progress in the global medical wound care arena.
"Early acceptance and sales of medical honey products means we can accelerate the development of next generation products," Boyd says.
Comvita Medical division manager Ray Lewis adds that international recognition of Comvita's range of patented wound dressings is growing at a rapid rate. Distribution agreements are already underway and more are in the pipeline for territories around the world.
"This manufacturing agreement has been part of Comvita's plan to bring a larger product range to the market, we are right on track," says Lewis.
A New Zealand-based clinical trial, currently underway, is measuring against standard treatment the healing effect of Manuka honey as a treatment for leg ulcers in the elderly. The 'Honey as Adjuvant Leg Ulcer Therapy' or HALT trial is recruiting patients through district nurses from the central Auckland, Counties Manukau and Waikato District Health Boards, and Christchurch's Nurse Maude Association.
Brightwake is a private limited liability company founded in 1979 offering a full contract manufacturing service to the medical industry. It specialises in making medical and technical products including dressings, pads, bandages, straps and technical fabrics.
No comments yet
Comvita may not increase earnings in 2014 as higher honey prices bite, Craigs says
Comvita turned to a loss in first half, remains confident of increasing annual profit
Nasdaq-listed Derma Sciences takes 7.3 percent stake in Comvita in discounted placement
Comvita FY profit falls 10 percent , beating guidance, on honey shortage, rising costs
Comvita flags 15 percent fall in FY profit as expensive honey, supply shortages prompt downgrade
Comvita buys Aussie groves to expand olive extract output
Comvita first-half earnings fall 7.4% amid short supply
Comvita buys Whanganui-based Kiwi Honey for undisclosed sum
Comvita hits 5-yr high on early results from diabetes trial
Comvita to seek deeper pool for directors' fees at AGM
